Takemura, K.; Takizawa, E.; Tamori, A.; Nakamae, M.; Kubota, H.; Uchida-Kobayashi, S.; Enomoto, M.; Kawada, N.; Hino, M.
Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C. Int. J. Mol. Sci. 2020, 21, 4517.
https://doi.org/10.3390/ijms21124517
AMA Style
Takemura K, Takizawa E, Tamori A, Nakamae M, Kubota H, Uchida-Kobayashi S, Enomoto M, Kawada N, Hino M.
Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C. International Journal of Molecular Sciences. 2020; 21(12):4517.
https://doi.org/10.3390/ijms21124517
Chicago/Turabian Style
Takemura, Kazuya, Etsuko Takizawa, Akihiro Tamori, Mika Nakamae, Hiroshi Kubota, Sawako Uchida-Kobayashi, Masaru Enomoto, Norifumi Kawada, and Masayuki Hino.
2020. "Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C" International Journal of Molecular Sciences 21, no. 12: 4517.
https://doi.org/10.3390/ijms21124517
APA Style
Takemura, K., Takizawa, E., Tamori, A., Nakamae, M., Kubota, H., Uchida-Kobayashi, S., Enomoto, M., Kawada, N., & Hino, M.
(2020). Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C. International Journal of Molecular Sciences, 21(12), 4517.
https://doi.org/10.3390/ijms21124517